ClinicalTrials.gg
RecruitingNCT07688915Updated Jul 7, 2026

High-Intensity Laser Therapy Versus Transforaminal Epidural Steroid Injection in Chronic Lumbar Disc Herniation-Related Low Back and Radicular Pain

An interventional study of High-Intensity Laser Therapy and Transforaminal Epidural Steroid Injections in Lumbar Disc Herniation, Chronic Low Back Pain and Radicular Pain, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Aug 2025, registered Jun 2026).
  • Started Aug 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This prospective, randomized, single-blinded, controlled clinical trial aims to compare the effectiveness of high-intensity laser therapy and fluoroscopy-guided transforaminal epidural steroid injection in patients with chronic low back pain and lumbar radiculopathy. Eligible patients will be randomized into two parallel groups. One group will receive high-intensity laser therapy, and the other group will receive transforaminal epidural steroid injection. All participants will also receive a standardized home-based exercise program. Outcomes will be assessed at baseline, 2 weeks, 6 weeks, and 12 weeks after treatment. The primary outcome will be pain intensity measured by the Visual Analog Scale. Secondary outcomes will include functional disability, neuropathic pain symptoms, quality of life, and functional walking capacity.

Read the detailed description

Low back pain is one of the most common musculoskeletal complaints and may lead to substantial disability and reduced quality of life. Lumbar disc herniation is a frequent cause of chronic axial and radicular low back pain.

High-intensity laser therapy is a non-invasive physical therapy modality with analgesic, anti-inflammatory, and biostimulatory effects. Transforaminal epidural steroid injection is a minimally invasive interventional treatment commonly used for radicular pain associated with lumbar disc herniation.

This prospective randomized controlled trial will include adult patients aged 18 to 65 years with chronic axial and radicular low back pain due to lumbar disc herniation. Participants will be randomized into two parallel groups. One group will receive high-intensity laser therapy for 15 sessions over 3 weeks, and the other group will receive fluoroscopy-guided transforaminal epidural steroid injection. All participants will receive a standardized home-based exercise program. Outcomes will be assessed at baseline, 2 weeks, 6 weeks, and 12 weeks after treatment.

02

Conditions studied

  • Lumbar Disc Herniation
  • Chronic Low Back Pain
  • Radicular Pain
  • Lumbar Radiculopathy

Keywords

  • High-intensity laser therapy
  • Transforaminal epidural steroid injection
  • Lumbar disc herniation
  • Chronic low back pain
  • Radicular pain
  • Lumbar radiculopathy
  • Visual analog scale
  • Oswestry Disability Index
03

In context

Intervertebral Disc Displacement

474 studies on the registry are indexed under Intervertebral Disc Displacement; 100 are open to participants now.

This study's planned enrollment of 24 is below the median of 63 across 344 interventional studies indexed under Intervertebral Disc Displacement.

Browse Intervertebral Disc Displacement studies →

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 443 studies on the registry; 111 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Diagnosis of lumbar disc herniation confirmed by clinical examination and lumbar magnetic resonance imaging
  • Chronic axial low back pain and radicular pain related to lumbar disc herniation
  • Low back and/or radicular pain lasting longer than 3 months
  • Resting low back and/or radicular pain intensity of ≥5 on a 0-10 visual analog scale
  • Willingness to participate in the study and provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or suspected pregnancy
  • Presence of a cardiac pacemaker
  • History of epilepsy
  • Active or previous
  • History of spinal surgery
  • Uncontrolled systemic or psychiatric disease
  • Cauda equina syndrome or progressive neurological deficit
  • Peripheral neuropathy, including diabetic or alcohol-related neuropathy
  • Neurodegenerative disease
  • Acute trauma
  • Active systemic infection
  • Local infection or skin disease at the injection site or treatment area
  • greater than 40 kg/m²
  • Bleeding disorder that contraindicates treatment
  • Spinal stenosis, spondylolysis, or spondylolisthesis
  • Neurogenic bladder or bowel syndrome
  • Rheumatologic disease
  • Arterial vascular disease or vascular claudication
  • Receipt of other physical therapy modalities within the last 3 months
  • Receipt of spinal injection therapy within the last 3 months
  • History of allergy to injection agents
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    High-Intensity Laser Therapy

    Participants in this group will receive high-intensity laser therapy using a pulsed Nd:YAG laser device for 15 sessions over 3 weeks. Treatment will be applied to the lumbar paravertebral region using the lumbosciatalgia mode. All participants will also receive a home exercise program.

    Device: High-Intensity Laser Therapy

  • Active comparator
    Transforaminal Epidural Steroid Injection

    Participants in this group will receive fluoroscopy-guided transforaminal epidural steroid injection. The injection level will be determined according to physical examination and lumbar magnetic resonance imaging findings. All participants will also receive a home exercise program.

    Procedure: Transforaminal Epidural Steroid Injections

Interventions

  • DeviceHigh-Intensity Laser Therapy

    High-intensity laser therapy will be applied using a pulsed Nd:YAG laser with a wavelength of 1064 nm. Treatment will be delivered in 15 sessions over 3 weeks to the lumbar paravertebral region. Each session will last approximately 10-12 minutes with a total energy dose of 2500 joules.

  • ProcedureTransforaminal Epidural Steroid Injections

    Fluoroscopy-guided transforaminal epidural steroid injection will be performed by an experienced physical medicine and rehabilitation specialist. After confirmation of needle placement with contrast medium, 2 mL of 2% lidocaine hydrochloride and 8 mg/2 mL dexamethasone will be administered.

06

What researchers measure

Primary outcomes

  1. Change in Low Back and Leg Pain Intensity Assessed by Visual Analog Scale

    Pain intensity at rest will be assessed using the visual analog scale. Participants will be asked to indicate their current low back and radicular leg pain intensity on a 10-cm horizontal line, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity.

    Time frame: Baseline, 2 weeks, 6 weeks, and 12 weeks after treatment

Secondary outcomes

  1. Change in Disability Assessed by the Oswestry Disability Index

    Disability related to low back pain will be assessed using the Oswestry Disability Index. The questionnaire includes 10 sections evaluating pain intensity and the effect of pain on daily activities. The total score is converted to a percentage from 0 to 100, with higher scores indicating greater disability.

    Time frame: Baseline, 2 weeks, 6 weeks, and 12 weeks after treatment

  2. Change in Neuropathic Pain Assessed by the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale

    Neuropathic pain features will be assessed using the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale. The scale consists of symptom-based and examination-based items. A total score of 12 or higher suggests neuropathic pain, while a score below 12 suggests nociceptive pain.

    Time frame: Baseline, 2 weeks, 6 weeks, and 12 weeks after treatment

  3. Change in Health-Related Quality of Life Assessed by the Short Form-36 Health Survey

    Health-related quality of life will be assessed using the Short Form-36 Health Survey. The questionnaire includes eight domains: physical functioning, role limitations due to physical health, role limitations due to emotional problems, vitality, mental health, social functioning, bodily pain, and general health perception. Each domain is scored from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline, 2 weeks, 6 weeks, and 12 weeks after treatment

  4. Change in Functional Walking Capacity Assessed by the Six-Minute Walk Test

    Functional walking capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible along a flat walking area for 6 minutes. The total distance walked in meters will be recorded, with longer distances indicating better functional walking capacity.

    Time frame: Baseline, 2 weeks, 6 weeks, and 12 weeks after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to privacy and ethical restrictions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2026, 14 months after the start.

Of 178 non-industry interventional studies with no phase under Intervertebral Disc Displacement, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 14 months is above that.

Counting every sponsor, half of 191 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 7, 2026
StartActual
Aug 1, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07688915
Responsible party
Esra Ülgen Kıratlıoğlu (MD, Ankara City Hospital Bilkent) — Principal investigator
First posted
Jul 7, 2026
Start date
Aug 1, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Jul 7, 2026

Study contacts

Esra Ülgen Kıratlıoğlu, MD
Contact
esraulgen@gmail.com
+905079614194

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion